Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Assets Average (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed Assets Average for 6 consecutive years, with $370.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Assets Average fell 28.25% to $370.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $370.9 million, a 28.25% decrease, with the full-year FY2024 number at $454.6 million, up 5.37% from a year prior.
  • Assets Average was $370.9 million for Q1 2025 at Pliant Therapeutics, down from $502.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $586.4 million in Q2 2023 to a low of $209.1 million in Q1 2022.
  • A 5-year average of $394.7 million and a median of $370.9 million in 2025 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 126.78% in 2023, then fell 28.25% in 2025.
  • Pliant Therapeutics' Assets Average stood at $227.7 million in 2021, then skyrocketed by 59.84% to $363.9 million in 2022, then soared by 44.63% to $526.3 million in 2023, then fell by 4.49% to $502.7 million in 2024, then decreased by 26.22% to $370.9 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Assets Average are $370.9 million (Q1 2025), $502.7 million (Q2 2024), and $516.9 million (Q1 2024).